Payload Information
General Information of This Payload
| Payload ID | PAY0UDHPX |
|||||
|---|---|---|---|---|---|---|
| Name | U-029 |
|||||
| Synonyms |
U-029
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
| Formula | C43H70N6O9 |
|||||
| Isosmiles | CC(C)[C@@H](C(N[C@@H](C(N([C@H]([C@@H](CC(N1[C@H]([C@H](OC)[C@H](C(N[C@@H](CC2=CC=CC=C2)C(N[C@H]3C(OCC3)=O)=O)=O)C)CCC1)=O)OC)[C@H](CC)C)C)=O)C(C)C)=O)NC |
|||||
| InChI |
InChI=1S/C43H70N6O9/c1-12-27(6)37(48(9)42(54)36(26(4)5)47-41(53)35(44-8)25(2)3)33(56-10)24-34(50)49-21-16-19-32(49)38(57-11)28(7)39(51)46-31(23-29-17-14-13-15-18-29)40(52)45-30-20-22-58-43(30)55/h13-15,17-18,25-28,30-33,35-38,44H,12,16,19-24H2,1-11H3,(H,45,52)(H,46,51)(H,47,53)/t27-,28+,30+,31-,32-,33+,35-,36+,37-,38+/m0/s1
|
|||||
| InChIKey |
DJSACLLXNRDOMH-VCMYFHNKSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
815.066 |
Polar area |
184.71 |
||
Complexity |
1464.108243 |
xlogp Value |
2.4507 |
|||
Heavy Count |
58 |
Rot Bonds |
22 |
|||
Hbond acc |
10 |
Hbond Donor |
4 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
aU2023279443A1 Example A5 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
A mixed solvent of PBS and and Matrigel was used to prepare a cell suspension of 5.0x107 cells / mL. The prepared cell suspension was subcutaneously injected to the right flank region of female BALB/c-nu/nu mice at 0.1 mL per mouse. Individuals having a tumor volume within a range of 50 to 500 mm 3 were selected. test compound at a concentration of 3 mg/kg or the solvent alone was intravenously administered. the tumor volume was measured at Day 0 and Day 21.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87 female BALB/c-nu/nu mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition rate (%) | > 14% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell growth inhibition test was carried out on HER2-positive human gastric cancer cell line (NCI-N87), the cells were treated with a test compound or an anti-HER2 antibody (trastuzumab) at a concentration of 100 ng/mL. The cells were cultured for 6 days, then CellTiter-Glo was added and the luminescence amount was measured.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||